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Signiﬁcant improvement of portopulmonary hypertension
after 1-week terlipressin treatmentq
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3Hepato-Gastroenterology Unit, University of Ioannina, Medical School, 45110 Ioannina, GreeceCirrhosis associated with moderate and severe portopulmonary hypertension carries a poor prognosis. Optimal manage-
ment has not yet been deﬁned. Current treatment options, such as prostacyclin analogues, endothelin antagonists, and
phosphodiesterase-5 inhibitors, are characterized by slow onset of action and various adverse eﬀects, particularly in
patients with advanced cirrhosis. Here, we report the signiﬁcant reduction of pulmonary arterial pressure after 1-week
terlipressin treatment in a patient with concomitant hepato-renal syndrome. Terlipressin could be a novel and safe
treatment for portopulmonary hypertension.
 2008 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
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Portopulmonary hypertension (PPHTN) is deﬁned as
pulmonary arterial pressure (PAP) > 25 mmHg, pulmon-
ary vascular resistance (PVR) > 120 dynes s cm5, and
pulmonary capillary wedged pressure (PCWP) <
15 mmHg as assessed by right heart catheterization
(RHC) [1]. The presence ofmoderate (PAP35–44 mmHg)
or severe (PAP > 45 mmHg) PPHTN in cirrhotic patients
tends towards a poor outcome [2]. Optimal management
of PPHTNhas not yet been clearly deﬁned. Current treat-
ment options, such as prostacyclin analogues (epoprost-0168-8278/$34.00  2008 Published by Elsevier B.V. on behalf of the Europ
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E-mail address: etsianos@cc.uoi.gr (E.V. Tsianos).enol), endothelin antagonists (bosentan), and phospho-
diesterase-5 inhibitors (sildenaﬁl) require several weeks
or months to prove their eﬃcacy or/and may deteriorate
systemic haemodynamics and renal function in patients
with advanced cirrhosis.
Terlipressin has been reported to decrease PAP in
cirrhotic patients with mild (25–34 mmHg) pulmonary
hypertension (PH) [3]. Here, we report on the adminis-
tration of terlipressin in a patient with hepato-renal
syndrome (HRS) and concomitant severe PPHTN,
which signiﬁcantly improved pulmonary haemodynam-
ics concurrently with the amelioration of renal function.
Successive measurements of PAP and PVR were per-
formed using Doppler echocardiography, a technique
that is assuming an increasing role in the diagnosis
and follow-up of patients with PH [4].2. Case report
A 37-year-old man with cryptogenic cirrhosis (Child’s
status C), diagnosed histologically 4 years previously,
presented with oliguria and rest dyspnoea. Dyspnoeaean Association for the Study of the Liver.
Table 1
Eﬀects of terlipressin on pulmonary haemodynamics, systemic haemodynamics, and renal function






Systolic pulmonary arterial pressure (mmHg) 47 27 15 49 <25
Pulmonary vascular resistance (dynes s cm5) 320 140 80 300 <120
Right heart catheterization
Mean pulmonary arterial pressure (mmHg) 46 <25
Mean pulmonary vascular resistance (dynes s cm5) 350 <120
Pulmonary capillary wedge pressure (mmHg) 13 <15
Systemic haemodynamics and renal function
Mean arterial pressurea (mmHg) 70.8 85 92 89.2
Cardiac output (L/min)b 4.8 5.5 5.6 5
Systemic vascular resistance (dynes s cm5)c 1475 1545 1642
Serum creatinine (mg/dl) 3 2.3 1.4 1.1 0.6–1.2
Creatinine clearance (ml/min) 22.5 26 65 107–139
Urinary volume (ml/24 h) 400 1900 2450
Urinary sodium (mmol/24 h) 4.4 81.7 110
a Calculated as diastolic arterial pressure + [(systolic–diastolic arterial pressure)/3].
b Assessed by Doppler echocardiography.
c Calculated as mean arterial pressure/cardiac output.
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occurred in the last few months prior to admission
despite augmented diuretic therapy (spironolactone
100 mg/d and furosemide 200 mg/d). On examination,
he had ascites and marked peripheral oedema. Labora-
tory results showed low normal albumin values, and a
2-fold increase in creatinine levels, occurring over the
previous two weeks, with low creatinine clearance and
absence of intrinsic nephropathy. The arterial oxygen
saturation was 92% while breathing room air. Pulmon-
ary function tests showed 67% of normal values; a diﬀu-
sion capacity test was normal. There was no evidence of
infection or hypovolemia. Renal failure continued to
deteriorate despite discontinuation of diuretics, fulﬁlling
the criteria of HRS type 1. Transthoracic echocardiog-
raphy revealed right ventricular and atrial dilatation
with moderate tricuspid regurgitation and PH (Table
1); no pulmonary shunting was observed.
Intravenous terlipressin (1 mg four times daily) and
human albumin were initiated while furosemide was
reintroduced aiming at an inferior vena cava pressure,
assessed by in-mode echocardiography, below
10 mmHg. After 2 weeks of terlipressin treatment, his
symptoms, systemic haemodynamics, and renal function
markedly improved. Repeated echocardiography on
days 8 and 15 demonstrated markedly improved pul-
monary haemodynamics. Consequently, terlipressin
was discontinued and the patient was referred to a trans-
plant center for further evaluation. RHC and echocar-
diographic assessment of pulmonary haemodynamics 1
week oﬀ terlipressin were consistent with relapse of
severe PPHTN. Bosentan therapy 62.5 mg twice daily
was started, but was associated with recurrence of renalfailure, which responded to a 5-day course of terlipres-
sin. Thereafter, bosentan was maintained at a reduced
dose, while terlipressin became unavailable for over a
month due to lack of hospital pharmacy supplies. Dur-
ing this period, renal function worsened again and the
patient gradually developed right heart failure and ana-
sarca, requiring continuous hemoﬁltration.3. Discussion
Cirrhotic patients with PAP > 35 mmHg and
PVR > 400 dynes s cm5 prior to liver transplantation
(LT) have a signiﬁcant intraoperative and postoperative
mortality and should receive pulmonary vasodilator
treatment before attempting LT [2]. Several medications
have been considered in the management of PPHTN.
Epoprostenol is eﬃcacious, but adverse eﬀects in terms
of safety and tolerability, and drug delivery via continu-
ous infusion for several months, represent major draw-
backs [1,2]. Bosentan is probably the therapy of choice,
however, endothelin antagonists can worsen hepatic dys-
function and deteriorate renal failure in patients with type
2 HRS [2,5]. On the other hand, sildenaﬁl, by facilitating
nitric oxide production, may deteriorate hyperdynamic
circulation and portal hypertension [6]. Furthermore,
the slow onset of action is another major drawback for
all of the above mentioned agents.
Data regarding renal function in patients with PPHTN
are lacking though the same substances, not metabolized
by the diseased liver, have been involved in both renal [7]
and pulmonary arterial vasoconstriction [2]. To our
knowledge, co-existence of PPHTN and HRS has not
680 G. Kalambokis et al. / Journal of Hepatology 48 (2008) 678–680yet been reported. Type 1 HRS is a rapidly progressive
functional renal failure complicating end-stage cirrhosis,
and carries a poor prognosis. Current management
focuses on improving renal function with vasoconstrictor
treatment and thereby extending survival pending LT.
The vasopressin analogue terlipressin reduces portal pres-
sure and improves hyperdynamic circulation and func-
tional renal failure in cirrhotic patients mainly through
arterial vasoconstriction via stimulation of mesenteric
V1 receptors [7]. Terlipressin is well tolerated and signiﬁ-
cant adverse eﬀects are infrequent [8].
In the present case, a signiﬁcant amelioration of PH
was noted after just 1 week of terlipressin therapy.
Vasopressin receptors have been recognized in the pul-
monary arterial circulation [9,10]. Arginine–vasopressin
induces a dose-dependent pulmonary arterial vasocon-
striction in animal models without PH, possibly via
activation of V2 receptors, overriding an initial V1
stimulated vasodilatory response [11]. Likewise, in cir-
rhotic patients without PH, terlipressin increases PAP
and PCWP possibly through a direct eﬀect [12,13], since
the correction of the high ﬂow-state of cirrhosis could
be expected to decrease PAP [1]. On the other hand,
terlipressin has been shown to improve pulmonary hae-
modynamics in PH experimental models and aﬀected
individuals with or without cirrhosis [3,14–16]. Vaso-
pressin and its analogues may therefore have diﬀeren-
tial eﬀects on the pulmonary and systemic circulation
in patients with PPHTN, possibly due to receptor
remodeling [14], allowing systemic haemodynamics to
be supported without detrimental eﬀects on the pul-
monary circulation. Terlipressin may also improve
pulmonary haemodynamics in PPHTN by reducing
portal hypertension, which is the primary instigator of
PH [2].
PVR discriminates PPHTN from a hyperdynamic
circulatory state and is a therapeutic target in PPHTN
patients receiving vasodilatory treatment [1,2]. Echo-
cardiographic estimation of PVR has not yet been
employed in the management of patients with PPHTN,
though it has been shown to be comparable to RHC
in non-cirrhotic subjects with PH [4,17,18]. Whether,
non-invasive evaluation of PVR in addition to PAP
could add diagnostic accuracy in the detection of
patients with PPHTN constitutes a subject of future
research.
In conclusion, the pulmonary haemodynamic eﬀects
of terlipressin in cirrhotic patients warrant further inves-
tigation. Terlipressin could be of beneﬁt in patients with
PPHTN, and particularly in those with end-stage cirrho-
sis and/or concurrent renal failure, allowing a prompt
decrease in pulmonary pressures.References
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